OXYGENTAPH

OXYGENTA PHARMACEUTICAL financials

Market cap
₹205 Cr

Quarterly results

Q1 FY27: revenue up 144.5%, net profit up 65.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue14 33 49 15 14 +2%34 +2%50 +0%37 +145%
EBITDA-2 -4 -2 -7 -5 −111%-4 +6%0 +107%1 +108%
Net profit-3 -4 -2 -6 -5 −73%-5 −23%-2 +21%-2 +66%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −21.6% 1Y

₹50.0₹60.0₹70.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹71.26 on 10 Sept 2025 → ₹55.88. High ₹71.99 (12 Sept 2025), low ₹44.61 (11 Jun 2026).

Financials, as filed

Revenue grew 68.8% a year over 2 years, FY24 to FY26. Operating margin widened to -13.6%.

Year endingFY24FY25FY26
Revenue₹40 Cr₹109 Cr₹113 Cr
Operating profit₹-10 Cr₹-10 Cr₹-15 Cr
Operating margin-24.5%-9.1%-13.6%
Interest₹2 Cr₹4 Cr₹5 Cr
Depreciation₹3 Cr₹2 Cr₹2 Cr
Net profit₹-3 Cr₹-10 Cr₹-18 Cr
Net margin-8.8%-9.4%-15.6%
Cash from operations₹-13 Cr₹3 Cr₹-28 Cr
Free cash flow₹-17 Cr₹-8 Cr₹-41 Cr
ROCE-42.0%-33.0%-34.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹10 Cr₹14 Cr₹14 Cr₹33 Cr₹37 Cr₹37 Cr
Reserves₹-48 Cr₹-49 Cr₹-60 Cr₹-54 Cr₹-74 Cr₹-80 Cr
Borrowings₹48 Cr₹52 Cr₹68 Cr₹57 Cr₹73 Cr₹110 Cr
Other liabilities₹24 Cr₹14 Cr₹32 Cr₹26 Cr₹81 Cr₹53 Cr
Total liabilities₹34 Cr₹31 Cr₹54 Cr₹63 Cr₹117 Cr₹120 Cr
Fixed assets₹16 Cr₹20 Cr₹28 Cr₹29 Cr₹41 Cr₹48 Cr
Capital work in progress₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹17 Cr₹11 Cr₹26 Cr₹34 Cr₹75 Cr₹72 Cr
Total assets₹34 Cr₹31 Cr₹54 Cr₹63 Cr₹117 Cr₹120 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters trimmed −1.42 pp while the public added +1.41 pp. The shareholder count grew 1% to 10,196.

Promoters
56.5%
DIIs
0.0%
Public
43.4%

Since Jun 2025

  • Promoters −1.42 pp
  • Public +1.41 pp
  • DIIs 0.00 pp

How it drifted, 12 quarters

Over this window the public fell from 70.2% to 43.4% — −26.8 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 29.7%, DIIs 0.0%, Public 70.2%.Dec '23: Promoters 29.7%, DIIs 0.0%, Public 70.2%.Mar '24: Promoters 29.7%, DIIs 0.0%, Public 70.2%.Jun '24: Promoters 33.7%, DIIs 0.0%, Public 66.3%.Sep '24: Promoters 53.3%, DIIs 0.0%, Public 46.7%.Dec '24: Promoters 51.1%, DIIs 0.0%, Public 48.8%.Mar '25: Promoters 51.1%, DIIs 0.0%, Public 48.8%.Jun '25: Promoters 58.0%, DIIs 0.0%, Public 42.0%.Sep '25: Promoters 58.0%, DIIs 0.0%, Public 42.0%.Dec '25: Promoters 55.9%, DIIs 0.0%, Public 44.0%.Mar '26: Promoters 56.5%, DIIs 0.0%, Public 43.4%.Jun '26: Promoters 56.5%, DIIs 0.0%, Public 43.4%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of OXYGENTA PHARMACEUTICAL LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Virupaksha Organics Limited 56.50%unchanged
Sravani Reddy Gantla 6.78%unchanged
Subba Reddy Bhimavarapu 4.14%unchanged
Sunil V. Chawda 2.97%unchanged
Kumuda Katasani 2.27%unchanged
Aakanksha M Chawda 1.54%unchanged
Manoj S. Chawda 1.54%unchanged
Snigdha Vankineni 1.47%unchanged
Devarapally Venkateswara Reddy 1.31%unchanged
Satyanarayana Reddy Bandi 1.29%unchanged
B Subba Reddy 1.26%unchanged
Chandra Mouliswar Reddy Gangavaram 0.03%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse OXYGENTA PHARMACEUTICAL LIMITED

Guides on how to read this kind of business and the numbers that matter.